Zacks Investment Research
05 Aug 2026, 16:51 UTC · 1h ago
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
05 Aug 2026, 16:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Ultragenyx Pharmaceutical reported Q2 2026 revenues of $214 million, exceeding the Zacks Consensus Estimate of $181 million. — A significant beat on the top line and the achievement of record quarterly revenue typically drive positive investor sentiment.
+0.60Ultragenyx reported a Q2 2026 loss of 90 cents per share, which was narrower than the estimated loss of $1.27 per share. — Beating earnings estimates by reducing losses suggests improving operational efficiency or better-than-expected cost management.
+0.40Total revenues for Ultragenyx increased 28.1% year over year, driven largely by Crysvita's total revenues growing 28.9% to $156 million. — Strong double-digit growth in the company's primary product demonstrates sustainable commercial momentum.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
Reported record quarterly revenues and a loss that was narrower than consensus estimates.
Mentioned in the context of a collaboration agreement without any specific news affecting its valuation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
